Stargardt Disease (STGD) - Epidemiology Forecast - 2034

Key Highlights

• The analyst's analyst projects that the total number of Opioid withdrawal syndrome cases in 7MM were approximately 8,169,411 in 2022 and these cases are further expected to decrease during the forecasted period (2023-2034).
• According to the analyst's analysis, the total number of opioid misuse cases in the US was found to be 9,264,786 in 2022 and is estimated to decline with a significant CAGR throughout the forecast period (2023-2034).
• In 2022, the total number of cases with long-term opioid usage was 9,077,124 in the 7MM, which is anticipated to decrease during the study period [2020-2034].
• According to the analyst's estimates, the US alone accounted for 85% of the total Opioid Misuse Cases in the 7MM in 2022.

This report delivers an in-depth understanding of Opioid Withdrawal Syndrome, historical and forecasted epidemiology of Opioid Withdrawal Syndrome in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Opioid Withdrawal Syndrome Disease Understanding

Opioid Withdrawal Syndrome Overview

Opioid withdrawal is a constellation of symptoms that occurs after abrupt cessation, therapeutic discontinuation, or dosage reduction of opioids (ie, µ-receptor agonists), or after administration of an opioid antagonist (naltrexone or naloxone) or in some cases partial opioid agonist (buprenorphine) to a person who is physically dependent on opioids as a result of persistent, regular use.

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, signs and symptoms of opioid withdrawal include lacrimation or rhinorrhea, piloerection "goose flesh," myalgia, diarrhea, nausea/vomiting, pupillary dilation, photophobia, insomnia, autonomic hyperactivity (tachypnea, hyperreflexia, tachycardia, sweating, hypertension, hyperthermia), and yawning.

Opioid Withdrawal Syndrome Diagnosis

Although there is no diagnostic test for opioid withdrawal, urine toxicology must be checked to rule out withdrawal from any other drugs or combination of drugs. Urine toxicology is positive for most opioids such as morphine, heroin, codeine, oxycodone, and propoxyphene) for 12 to 36 hours after use. Methadone, buprenorphine, and LAAM (L-alpha-acetylmethadol) will not be detected in positive urine opiate tests, and they must be specifically tested. Urine toxicology for other drugs (marijuana, cocaine, benzodiazepine, and amphetamines) may also be commonly positive in opiate users. ECG, complete blood count (CBC), blood alcohol level, and basic metabolic panel (BMP) should also be done. COWS (Clinical Opioid Withdrawal Scale) assessment for opioid withdrawal is commonly used to determine the severity of opioid withdrawal.

Opioid Withdrawal Syndrome Epidemiology

As the market is derived using the patient-based model, the Opioid Withdrawal Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Number of Opioid misuse cases, Number of cases with long-term opioid usage, and Total Opioid Withdrawal Syndrome Cases in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

According to estimations, 10,867,527 case of Opioid misuse were found in 2022 in the 7MM.

As per the analyst's estimations, the total number of cases with opioid withdrawal syndrome in the United States were approximately 7,087,561 in 2022 and are projected to decrease during the forecast period.

According to the analyst's estimates, the number of opioid misuse cases in EU4 and the UK were found to be approximately 1,365,293 in 2022.

The highest proportion of Opioid withdrawal syndrome cases was reported in Italy among the EU4 countries, while the least number of cases was found in Spain.

The estimates show the number of Opioid Withdrawal Syndrome cases in Japan was found to be 160,278 cases in 2022, which is estimated to decrease and reach 135,570 cases by 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Texas A and M University, College Station, TX, USA, Baylor College of Medicine, Houston, Texas, University of Southern California, USA, Bremen Institute of Drug Research, University of Bremen, Germany, Meiji Pharmaceutical University, Tokyo and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Opioid Withdrawal Syndrome, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Opioid Withdrawal Syndrome Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Number of Opioid Misuse cases
• Number of Cases with long-term Opioid Usage
• Total Opioid Withdrawal Syndrome Cases

Opioid Withdrawal Syndrome Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Opioid Withdrawal Syndrome Epidemiology Segmentation

Opioid Withdrawal Syndrome Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Opioid Withdrawal Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Opioid Withdrawal Syndrome?
• What is the historical and forecasted Opioid Withdrawal Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the long term opioid usage in Japan lower than the US?
• Which country has a high patient share for Opioid misuse ?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Opioid Withdrawal Syndrome prevalence cases in varying geographies over the coming years.
• A detailed overview of Opioid misuse and long term opioid usage cases is an inclusion.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Opioid Withdrawal Syndrome Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Opioid Withdrawal Syndrome (OWS) cases in 2022?

The highest cases of Opioid Withdrawal Syndrome was found in the UK among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Opioid Withdrawal Syndrome (OWS) cases in 2022?

The highest cases of Opioid Withdrawal Syndrome were found in the US among the 7MM in 2022.